Article
Oncology
Beatrice Cavalluzzo, Angela Mauriello, Concetta Ragone, Carmen Manolio, Maria Lina Tornesello, Franco M. Buonaguro, Siri Amanda Tvingsholm, Sine Reker Hadrup, Maria Tagliamonte, Luigi Buonaguro
Summary: This study aimed to identify HCC-specific overexpressed proteins and potential epitopes recognized by CD8(+) cytotoxic T cells that may share homology to viral epitopes. The results showed that circulating CD8(+) T cells targeted both HCC and viral-related epitopes, suggesting their potential use in HCC-specific immunotherapies.
Review
Pharmacology & Pharmacy
Wenqian Xu, Yuliang Cheng, Yahui Guo, Weirong Yao, He Qian
Summary: Hepatocellular carcinoma (HCC) contains a significant number of immune cell stroma, with tumor-associated macrophages (TAMs) playing a crucial role in HCC development. Targeting TAMs in HCC treatment has shown promising therapeutic outcomes by eliminating, blocking recruitment, reprogramming, and restoring TAMs functions.
BIOCHEMICAL PHARMACOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Xiao Wang, Keyan Wang, Cuipeng Qiu, Bofei Wang, Xiaojun Zhang, Yangcheng Ma, Liping Dai, Jian-Ying Zhang
Summary: This study found that autoantibody to GNAS could be a potential biomarker for the early detection of HCC. The autoantibody response to GNAS in patients at different stages was closely associated with the progression of chronic liver lesions. Additionally, high positive rates of GNAS autoantibody in AFP negative and early-stage HCC patients could supplement AFP in early detection of HCC.
Article
Biochemistry & Molecular Biology
Cuipeng Qiu, Yangcheng Ma, Bofei Wang, Xiaojun Zhang, Xiao Wang, Jian-Ying Zhang
Summary: This study analyzed the presence of autoantibodies to PAX5, PTCH1, and GNA11 in the sera of Hispanic Americans, including HCC patients, LC patients, CH patients, and normal controls, using an ELISA. The results showed that these autoantibodies could serve as biomarkers for the early detection of HCC and they may monitor the transition of high-risk patients to HCC.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Immunology
Cuipeng Qiu, Yaru Duan, Bofei Wang, Jianxiang Shi, Peng Wang, Hua Ye, Liping Dai, Jianying Zhang, Xiao Wang
Summary: The study found a positive correlation between the high expression of PDLIM1 autoantibodies in OC patients and high expression of PDLIM1 in tissues, indicating the potential of autoantibodies against PDLIM1 as a novel serological biomarker for OC, serving as a complementary measure to CA125 and improving the accuracy of OC detection.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Mengtao Xing, Xinzhi Wang, Robert A. Kiken, Ling He, Jian-Ying Zhang
Summary: Early detection and treatment of HCC are crucial for improving patient survival rates. Discovering specific biomarkers and understanding the immunological mechanisms are urgent, with the immune system playing a key role in the recognition and targeted therapy of HCC.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
Ping Tao, Liang Hong, Wenqing Tang, Qun Lu, Yanrong Zhao, Si Zhang, Lijie Ma, Ruyi Xue
Summary: This study comprehensively investigated immune patterns in HCC patients and correlated them with genomic characteristics and clinical outcomes. Patients were categorized into four immune subgroups with distinct clinical outcomes, revealing significant inter-tumoral and intra-tumoral immune heterogeneity based on in-depth interrogation of the immune landscape. This work may serve as a useful resource for establishing the immunoscore for prognostic prediction in HCC patients.
FRONTIERS IN ONCOLOGY
(2021)
Article
Cell Biology
Yangcheng Ma, Cuipeng Qiu, Bofei Wang, Xiaojun Zhang, Xiao Wang, Renato J. Aguilera, Jian-Ying Zhang
Summary: This study identified anti-DNMT3A, p16, HSPA5, and HSP60 autoantibodies as potential diagnostic biomarkers for Hispanic HCC patients. Combining all four autoantibodies increased sensitivity for Hispanic HCC diagnosis.
Article
Chemistry, Multidisciplinary
Junyang Wang, Chao Zheng, Yihui Zhai, Ying Cai, Robert J. Lee, Jianming Xing, Hao Wang, Helen H. Zhu, Lesheng Teng, Yaping Li, Pengcheng Zhang
Summary: This study suggests that synthetic high-density lipoproteins (sHDLs) can deliver drugs selectively to tumor cells, improving prognosis in patients with hepatocellular carcinoma. The findings show that VG-sHDLs induce the release of various molecules and cytokines from HCC cells, promoting differentiation into activated macrophages and enhancing immune cell activity, leading to improved tumor eradication.
Review
Oncology
Konstantinos Arvanitakis, Triantafyllia Koletsa, Ioannis Mitroulis, Georgios Germanidis
Summary: Hepatocellular carcinoma (HCC) is a major type of liver cancer, and inflammation plays a crucial role in tumor growth and metastasis through tumor-associated macrophages (TAMs). TAMs can have either anti-tumor or pro-tumor functions, and their presence is closely associated with HCC development. This review summarizes the role of TAMs in HCC pathogenesis and highlights their potential application in tumor therapy.
Review
Pharmacology & Pharmacy
Yi Yuan, Dailin Wu, Jing Li, Dan Huang, Yan Zhao, Tianqi Gao, Zhenjie Zhuang, Ying Cui, Da-Yong Zheng, Ying Tang
Summary: Tumor-associated macrophages (TAMs) are crucial in the immune cell stroma of hepatocellular carcinoma (HCC). TAMs originate from monocytic myeloid-derived suppressor cells, peripheral blood monocytes, and kupffer cells, and their recruitment and differentiation are influenced by various factors. TAMs interact with tumor cells and other immune cells through cytokines and extracellular vesicles, impacting processes such as carcinoma cell proliferation, invasion, migration, angiogenesis, and liver fibrosis progression.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Hsin-Lun Lee, Yi-Chieh Tsai, Narpati Wesa Pikatan, Chi-Tai Yeh, Vijesh Kumar Yadav, Ming-Yao Chen, Jo-Ting Tsai
Summary: Hepatocellular carcinoma is a common malignancy with high mortality rate. Radiotherapy is an effective non-surgical treatment option, but its efficacy is limited in advanced and recurrent tumors. Tumor-associated macrophages (TAMs) play a crucial role in radiotherapy response. In this study, we identified the potential of targeting the TAM/CXCL6/CXCR2 tumor immune signaling axis as a new treatment strategy for radiotherapy-resistant hepatocellular carcinoma cells.
Article
Gastroenterology & Hepatology
Valerie Paradis
Summary: The molecular analysis of primary liver malignancies helps refine pathological diagnosis and identify increasing subtypes of hepatocellular proliferation, aiding in patient prognosis and treatment selection. Hepatocellular carcinomas are heterogeneous malignant hepatocellular proliferations, occurring in patients with chronic liver diseases and fibrosis, some arising from malignant transformation of pre-existing hepatocellular adenomas. TERT promoter mutations are common genomic alterations that occur early in liver carcinogenesis, underscoring the importance of a more active biopsy strategy.
LIVER INTERNATIONAL
(2021)
Article
Oncology
Jiantao Fu, Feng Chen, Yuanji Lin, Jin Gao, Anna Chen, Jin Yang
Summary: This study identified five dysregulated and mutated tumor-specific antigens in hepatocellular carcinoma (HCC) and determined seven immune gene modules and five immune subtypes of HCC. According to the results, IS1 patients may be suitable for vaccination.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Hikmet Akkiz
Summary: Hepatocellular carcinoma (HCC) is a prevalent cancer that ranks fourth in cancer-related deaths globally. The tumor microenvironment (TME) formed by HCC cells and various stromal and inflammatory cells plays a crucial role in tumor growth, metastasis, and drug resistance. Cancer-associated fibroblasts (CAFs) are an important component of the TME and their signaling can contribute to drug resistance. However, CAFs display heterogeneity and can also have antitumor properties. Understanding the crosstalk between CAFs, HCC cells, and other stromal cells is essential for the development of effective targeted therapies for HCC.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)